.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
US Army
US Department of Justice
Johnson and Johnson
Healthtrust
Harvard Business School
UBS
Daiichi Sankyo
Fuji
Colorcon

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Screening of abundantly secreted proteins and their use as fusion partners for the production of recombinant proteins
Abstract: The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyzes. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.
Inventor(s): Sohn; Jung-Hoon (Chungbuk, KR), Bae; Jung-Hoon (Daejeon, KR), Kim; Hyun-Jin (Ulsan, KR), Lim; Kwang-Mook (Daejeon, KR)
Assignee: Korean Research Institute of Bioscience and Biotechnology (Daejeon, KR)
Application Number:12/631,449
Patent Claims:1. A method of identifying a secretion fusion partner (SFP), said method comprising: (i) transforming a first yeast host cell with a construct comprising a heterologous promoter operably linked to a polynucleotide encoding a secreted polypeptide; (ii) determining said secreted polypeptide to be over-secreted when the secretion level of said secreted polypeptide linked to the heterologous promoter is higher than that of said secreted polypeptide linked to a natural promoter thereof; (iii) transforming a second yeast host cell with a construct comprising a first polynucleotide encoding a target polypeptide and a second polynucleotide encoding the polypeptide determined to be over-secreted in step (ii), wherein said first and second polynucleotides are in any order relative to each other and are in the same frame; (iv) culturing said second yeast host cell under conditions wherein said construct expresses a fusion polypeptide of said target polypeptide and said over-secreted polypeptide; and (v) determining whether said fusion polypeptide is secreted into the culture medium; thereby identifying whether said over-secreted polypeptide is a SFP, wherein the SFP comprises a signal peptide, a hydrophilic domain, or a signal peptide and a hydrophilic domain, and the SFP comprises an amino acid sequence selected from the group consisting of amino acids 1-84 of SEQ ID NO: 84, amino acids 1-101 of SEQ ID NO: 84, amino acids 1-135 of SEQ ID NO: 84, amino acids 1-169 of SEQ ID NO: 84, amino acids 1-195 of SEQ ID NO: 84, amino acids 1-227 of SEQ ID NO: 84, amino acids 1-271 of SEQ ID NO: 84, amino acids 1-364 of SEQ ID NO: 84; or the SFP is selected from the group consisting of BGL2 (SEQ ID NO: 80), GAS3 (SEQ ID NO: 81), GAS5 (SEQ ID NO: 82), PST1 (SEQ ID NO: 83), SCW4 (SEQ ID NO: 84), SCW10 (SEQ ID NO: 85), SIMI (SEQ ID NO: 86), UTH1 (SEQ ID NO: 87), YGP1 (SEQ ID NO: 88), YPS1 (SEQ ID NO: 89), and ZPS1 (SEQ ID NO: 90); and wherein the target polypeptide is selected from the group consisting of an interleukin, a coagulation factor, an interferon-.alpha., -.beta. or -.gamma., a granulocyte-colony stimulating factor, a granulocyte macrophage-colony stimulating factor, a tissue growth factor, an epithelial growth factor, a TGF.alpha., a TGF.beta., an epidermal growth factor, a platelet-derived growth factor, a fibroblast growth factor, a follicle stimulating hormone, a thyroid stimulating hormone, an antidiuretic hormone, a pigmentary hormone, a parathyroid hormone, a luteinizing hormone-releasing hormone, a carbohydrate-specific enzyme, a proteolytic enzyme, a lipase, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, a ligase, an immunoglobulin, a cytokine receptor, a lactoferrin, a phospholipase A2-activating protein, an insulin, a tumor necrosis factor, a calcitonin, a calcitonin gene related peptide, an enkephalin, a somatomedin, an erythropoietin, a hypothalamic releasing factor, a prolactin, a chorionic gonadotropin, a tissue plasminogen activator, a growth hormone releasing peptide, a thymic humoral factor, an anticancer peptide, and an antibiotic peptide.

2. The method of claim 1, wherein said secreted polypeptide is selected as being abundantly expressed in a secretome.

3. The method of claim 2, wherein said secretome is isolated from yeast, bacteria, plants or animals.

4. The method of claim 1, further comprising determining an optimal size of said SFP for secretion of said fusion polypeptide or a second fusion polypeptide, wherein said optimal size is determined by deletion analysis of said SFP.

5. The method of claim 1, wherein said heterologous promoter is prokaryotic, eukaryotic or viral.

6. The method of claim 5, wherein said heterologous promoter is selected from the group consisting of bacteriophage lambda PR, bacteriophage lambda PL, lambda II, E. coli trp, E. coli recA, E. coli heat shock, E. coli lacZ, SV40 early, yeast GAPDH, PGK, ADH, PHO5, TEF, GAL1, GAL10, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, maloney virus, cytomegalovirus immediate early, Epstein Barr virus, Rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine, and human metallothionein.

7. The method of claim 1, wherein said secreted polypeptide is glycosylated.

8. The method of claim 1, wherein said first yeast host cell is a selected from the group consisting of Candida, Debaryomyces, Hansenula, Kluyveromyces, Pichia, Schizosaccharomyces, Yarrowia, Saccharomyces, Schwanniomyces, and Arxula.

9. The method of claim 8, wherein said first yeast host cell is selected from the group consisting of Candida utilis, Candida boidinii, Candida albicans, Kluyveromyces lactis, Pichia pastoris, Pichia stipitis, Schizosaccharomyces pombe, Saccharomyces cerevisiae, Hansenula polymorpha, Yarrowia lipolytica, Schwanniomyces occidentalis, and Arxula adeninivorans.

10. The method of claim 1, wherein said second yeast host cell is a selected from the group consisting of Candida, Debaryomyces, Hansenula, Kluyveromyces, Pichia, Schizosaccharomyces, Yarrowia, Saccharomyces, Schwanniomyces, and Arxula.

11. The method of claim 10, wherein said second yeast host cell is selected from the group consisting of Candida utilis, Candida boidinii, Candida albicans, Kluyveromyces lactis, Pichia pastoris, Pichia stipitis, Schizosaccharomyces pombe, Saccharomyces cerevisiae, Hansenula polymorpha, Yarrowia lipolytica, Schwanniomyces occidentalis, and Arxula adeninivorans.

12. The method of claim 1, wherein the target polypeptide is selected from the group consisting of human interleukin-2 (hIL-2), exendin-3, exendin-4 (EXD4), glucagon-like-peptide-1 (GLP-1), parathyroid hormone (PTH), human interleukin-1.beta., human interleukin-6, human interleukin-32.alpha., -32.beta. or -32.gamma., Factor VII, Factor VIII, Factor IX, human serum albumin, human interferon-.alpha., -.beta. or -.gamma., human granulocyte-colony stimulating factor, human granulocyte macrophage-colony stimulating factor, human growth hormone (hGH), human platelet-derived growth factor, human basic fibroblast growth factor, human epidermal growth factor (EGF), human insulin-like growth factor, human nerve growth factor, human transforming growth factor .beta.-1, human follicle stimulating hormone, glucose oxidase, glucodase, galactosidase, glucocerebrosidase, glucuronidase, asparaginase, arginase, arginine deaminase, peroxide dismutase, endotoxinase, catalase, chymotrypsin, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, bovine galactose-1-phosphate uridyltransferase, jellyfish green fluorescent protein, Candida antarctica lipase B, Candida rugosa lipase, fungal chloroperoxidase, .beta.-galactosidase, resolvase, .alpha.-galactosidase, .beta.-glucosidase, trehalose synthase, cyclodextrin glycosyl transferase, xylanase, phytase, human lactoferrin, human erythropoietin, human paraoxonase, human growth differentiation factor 15, human galectin-3 binding protein, human serine protease inhibitor, Kunitz type 2, human Janus kinase 2, human fms-like tyrosine kinase 3 ligand, human YM1 & 2, human CEMI, human diacylglycerol acyltransferase, human leptin, human mL259, human proteinase 3, human lysozyme, human DEAD box protein 41, human etoposide induced protein 24, mouse caspase1, bovine angiogenin, and earthworm lumbrokinase.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Nps Pharms Inc
NATPARA
parathyroid hormone
INJECTABLE;INJECTION1255110012015-01-23► Subscribe Korean Research Institute of Bioscience and Biotechnology (Daejeon, KR) Sohn; Jung-Hoon (Chungbuk, KR), Bae; Jung-Hoon (Daejeon, KR), Kim; Hyun-Jin (Ulsan, KR), Lim; Kwang-Mook (Daejeon, KR) ► SubscribeRXOrphansearch
Nps Pharms Inc
NATPARA
parathyroid hormone
INJECTABLE;INJECTION1255110022015-01-23► Subscribe Korean Research Institute of Bioscience and Biotechnology (Daejeon, KR) Sohn; Jung-Hoon (Chungbuk, KR), Bae; Jung-Hoon (Daejeon, KR), Kim; Hyun-Jin (Ulsan, KR), Lim; Kwang-Mook (Daejeon, KR) ► SubscribeRXOrphansearch
Nps Pharms Inc
NATPARA
parathyroid hormone
INJECTABLE;INJECTION1255110032015-01-23► Subscribe Korean Research Institute of Bioscience and Biotechnology (Daejeon, KR) Sohn; Jung-Hoon (Chungbuk, KR), Bae; Jung-Hoon (Daejeon, KR), Kim; Hyun-Jin (Ulsan, KR), Lim; Kwang-Mook (Daejeon, KR) ► SubscribeRXOrphansearch
Nps Pharms Inc
NATPARA
parathyroid hormone
INJECTABLE;INJECTION1255110042015-01-23► Subscribe Korean Research Institute of Bioscience and Biotechnology (Daejeon, KR) Sohn; Jung-Hoon (Chungbuk, KR), Bae; Jung-Hoon (Daejeon, KR), Kim; Hyun-Jin (Ulsan, KR), Lim; Kwang-Mook (Daejeon, KR) ► SubscribeRXOrphansearch
Merck
ELSPAR
asparaginase
VIAL1010630011978-01-10► Subscribe Korean Research Institute of Bioscience and Biotechnology (Daejeon, KR) Sohn; Jung-Hoon (Chungbuk, KR), Bae; Jung-Hoon (Daejeon, KR), Kim; Hyun-Jin (Ulsan, KR), Lim; Kwang-Mook (Daejeon, KR) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
China102239183Jun 30, 2017
China102239183Nov 09, 2011
China103952425Apr 12, 2017
China103952425Jul 30, 2014
European Patent Office2370470Apr 11, 2012
European Patent Office2370470Oct 05, 2011
European Patent Office2370470Oct 05, 2016
European Patent Office2573122Jul 10, 2013
European Patent Office2573122Mar 27, 2013
European Patent Office2918606Oct 28, 2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Federal Trade Commission
McKinsey
Colorcon
Teva
Harvard Business School
Covington
Baxter
Deloitte
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot